PMPreetha Madhukumar

Preetha Madhukumar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Preetha Madhukumar has a total of 82 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Male breast cancer: a Singapore perspective

    by Joshua S. H. Lim, Yirong Sim, Joanne Ngeow, Jeanette Yuen, Veronique K. M. Tan, Benita Kiat Tee Tan, Wei‐Sean Yong, Chow Yin Wong, Sue Zann Lim, Julie Liana B. Hamzah, et al.

    Introduction: Male breast cancer (MBC) is rare, representing <1% of all breast cancers. Treatment recommendations have been extrapolated from trial data of female breast cancer patients. This study aims to report our institutional experience of MBC across a 20 year period, analyse the survival outcome and prognosis of this group against female breast cancer patients treated at the same centre.Methods: Clinical, histopathological, treatment and survival data of male and female breast cancer patients treated between Jan 1999 and July 2019 at Singapore General Hospital and National Cancer Centre Singapore were identified and analysed.Results: Fifty‐seven male patients were identified. The median age at diagnosis was 63 years. Majority had invasive ductal carcinoma (86%) and presented at an early disease stage: 70.2% presented as Tis/T1/T2 and 49.1% had no axillary nodal involvement. 84.2% had a simple mastectomy with either a sentinel lymph node biopsy or axillary clearance. The median follow up was 5.69 years for males and 5.83 years for females. The median survival was 11.86 years for males and 16.3 years for females. At 5 years, overall survival (OS) was 69.9% (52.3–82.1%) and disease free survival (DFS) was 62.9% (44.9–76.5%) for males compared with OS 83.8% (83.21–84.39%) and DFS 74.5% (73.91–75.09%) for females.Conclusion: MBC remains understudied. Our institutional data indicates that good long term survival in South‐East Asian patients can be achieved with treatment protocols that are similar to female breast cancer. More prospective studies are required.


  • Multi-center evaluation of artificial intelligent imaging and clinical models for predicting neoadjuvant chemotherapy response in breast cancer

    by Tan Hong Qi, Ong Hiok Hian, Arjunan Muthu Kumaran, Tira J. Tan, Tan Ryan Ying Cong, Ghislaine Lee Su-Xin, Elaine Hsuen Lim, Raymond Ng, Ming Chert Richard Yeo, Faye Lynette Lim Wei Tching, et al.

    Background Neoadjuvant chemotherapy (NAC) plays an important role in the management of locally advanced breast cancer. It allows for downstaging of tumors, potentially allowing for breast conservation. NAC also allows for in-vivo testing of the tumors’ response to chemotherapy and provides important prognostic information. There are currently no clearly defined clinical models that incorporate imaging with clinical data to predict response to NAC. Thus, the aim of this work is to develop a predictive AI model based on routine CT imaging and clinical parameters to predict response to NAC. Methods The CT scans of 324 patients with NAC from multiple centers in Singapore were used in this study. Four different radiomics models were built for predicting pathological complete response (pCR): first two were based on textural features extracted from peri-tumoral and tumoral regions, the third model based on novel space-resolved radiomics which extract feature maps using voxel-based radiomics and the fourth model based on deep learning (DL). Clinical parameters were included to build a final prognostic model. Results The best performing models were based on space-resolved and DL approaches. Space-resolved radiomics improves the clinical AUCs of pCR prediction from 0.743 (0.650 to 0.831) to 0.775 (0.685 to 0.860) and our DL model improved it from 0.743 (0.650 to 0.831) to 0.772 (0.685 to 0.853). The tumoral radiomics model performs the worst with no improvement of the AUC from the clinical model. The peri-tumoral combined model gives moderate performance with an AUC of 0.765 (0.671 to 0.855). Conclusions Radiomics features extracted from diagnostic CT augment the predictive ability of pCR when combined with clinical features. The novel space-resolved radiomics and DL radiomics approaches outperformed conventional radiomics techniques.


  • Open Access

    Atypical Ductal Hyperplasia of the Breast on Core Needle Biopsy: Risk of Malignant Upgrade On Surgical Excision

    by Tiffany Sin Hui Bong, Jun Kiat Thaddaeus Tan, Juliana Teng Swan Ho, Puay Hoon Tan, Wing Sze Lau, Tuan Meng Tan, Jill Su Lin Wong, Veronique Kiak Mien Tan, Benita Kiat Tee Tan, Preetha Madhukumar, et al.

    Bong TS, et al. J Breast Cancer. 2022 Feb;25(1):37-48. https://doi.org/10.4048/jbc.2022.25.e7


  • Genetic differences between benign phyllodes tumors and fibroadenomas revealed through targeted next generation sequencing

    by Cedric Chuan Young Ng, Nur Diyana Md Nasir, Benjamin Nathanael Loke, Timothy Kwang Yong Tay, Aye Aye Thike, Vikneswari Rajasegaran, Wei Liu, Jing Yi Lee, Peiyong Guan, Abner Herbert Lim, et al.


  • Intrahepatic Biliary Cystadenoma Presenting with Obstructive Jaundice

    by Madhukumar Preetha, Alexander Y.F. Chung, Dennis T.H. Lim, Soo-Khim Lim-Tan, Choon-Hua Thng